ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment

		ReBuilder Medical Technologies logo. (PRNewsFoto/ReBuilder Medical Technologies, Inc.) CHARLES TOWN, WV UNITED STATES

    CHARLES TOWN, W.Va., Oct. 23 /PRNewswire-FirstCall/ -- After five
successful years of steady growth, ReBuilder Medical Technologies, Inc.
(Pink Sheets: RBRM) announced today that it is celebrating five years of
continued operations by shipping out its 50,000th order, and sales growth
that indicates reaching 100,000 orders by the end of 2008.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

    "Our ReBuilder for Diabetic Peripheral Neuropathy has been a steady
winner for us. Today we celebrate our 50,000th shipment. Some of these
orders were for the ReBuilder electronic device, some were for the
consumable support products that the patients consume, and others were for
the Phillips Molluscum Treatment System(TM) and its consumables. The
ReBuilder System(R) itself can stand alone, and produces 100% profit
margins, however, we have offered accessories and refills on its
consumables and all together, with the new customers and the returning
customers who re-order their supplies, we are happy to have reached this
milestone," says David B. Phillips, Ph.D. CEO of ReBuilder Medical
Technologies, Inc.

    "Our sales have been growing regularly and as a result of about 33% of
our sales coming from referrals from happy customers, and the new marketing
partners, we hope to ship an additional 50,000 orders, in the next year,
and have geared production, inventory control, and general management
practices accordingly. It takes new practices to cope with the sales and
customer service any company is accustomed to," said David B. Phillips,
Company CEO, at the end of this interview. The anticipated 50,000 shipments
should take us to the next level in mass marketing.

    About ReBuilder Medical Technologies, Inc.:

    ReBuilder Medical Technologies, Inc. is a manufacturer of medical
devices and innovative technologies founded by world-renowned medical
device inventor David B. Phillips, Ph.D. The company's flagship product is
its FDA registered ReBuilder System(R), used for treating peripheral
neuropathy. Unlike current therapies for neuropathy (nerve disease) that
depend on prescription drugs with powerful side effects, the ReBuilder
System(R) is a portable, battery-powered medical product that provides a
unique, non-surgical treatment which is non-invasive, has no side effects
and can actually strengthen muscles while increasing blood flow.

    ReBuilder Medical Technologies, Inc. also manufactures the Phillips
Molluscum Treatment System(TM) for treating the skin disease Molluscum
Contagiosum which primarily affects children. This system uses its
proprietary form of micronized amorphous silver ions to disable the
molluscum pathogen without side effects. The company is currently
performing research and development on a number of other products as well.

    ReBuilder Medical Technologies, Inc. is located in Charles Town, WV.
CEO, Dr. David Phillips, Ph.D. is best known for inventing the very first
infrared ear thermometer. Dr. Phillips also was responsible for the GST
System, which is used for the early detection of breast cancer, and the
AcuPen, a hand-held device that provides the benefits of acupuncture
without the use of needles.

    More information on ReBuilder Medical Technologies, Inc. and its
products can be found at: http://www.rebuildermedical.com.

    Safe Harbor: This letter contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended, which
are intended to be covered by the safe harbors created thereby. Investors
are cautioned that all forward-looking statements involve risks and
uncertainty, including without limitation, the ability of the Company to
successfully implement its turnaround strategy, changes in costs of raw
materials, labor, and employee benefits, as well as general market
conditions, competition and pricing. Although the Company believes that the
assumptions underlying the forward-looking statements contained herein are
reasonable, any of the assumptions could be inaccurate, and therefore,
there can be no assurance that the forward-looking statements included in
this letter will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein,
the inclusion of such information should not be regarded as representation
by the Company or any other person that the objectives and plans of the
Company will be achieved. In assessing forward-looking statements included
herein, readers are urged to carefully read those statements. When used in
the Annual Report on Form 10-K, the words "estimate," "anticipate,"
"expect," "believe," and similar expressions are intended to be
forward-looking statements.